16:19 EDT Tyra Biosciences sees cash, equivalents sufficient to execute plan through 2026
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
- Tyra Bioscience Expands Board with Two New Appointments
- Tyra Bioscience Gains Pediatric Disease Designation for Achondroplasia Drug Amid FDA Voucher Uncertainty
- Tyra Biosciences price target raised to $23 from $19 at H.C. Wainwright
- Tyra Biosciences files to sell 15.37M shares of common stock for holders